-1768251326553.webp&w=3840&q=75)
2025 MaTOS Lung | Session X | Targeted Therapy Forum-Part II Case-Based Panel Discussion
Overview
Dr. Karim presented Case 1, a 76-year-old with ROS1 fusion NSCLC showed progression on entrectinib due to resistance mutation; panel favored teletrectinib and stressed careful sequencing and diagnosis.
Case 2, presented by Dr. Gainor was a 66-year-old woman with RET fusion lung adenocarcinoma received RT. Panel favored selpercatinib for efficacy, CNS activity, and lower pneumonitis risk.
Dr. Das presented Case 3, a 60-year-old never-smoker with metastatic adenosquamous lung cancer and high PD-L1 responded dramatically to capmatinib after MET14 mutation discovery, highlighting value of targeted therapy.
Case 4, presented by Dr. Bazhenova was of a 26-year-old with HER2 exon 20 lung cancer relapsed after chemo and zangertinib; panel debated next steps including T-DXd and emerging therapies.
Dr. Sanborn presented Case 5, a 67-year-old with BRAF V600E metastatic lung cancer had durable control on BRAF/MEK therapy. With slow progression, panel debated continuing targeted therapy versus switching.
Dr. Alder presented Case 6, a 56-year-old with NTRK fusion lung cancer was treated with larotrectinib. Panel stressed RNA testing to avoid missed fusions and guide targeted therapy.
The wrap up panel discussion reviewed post-targeted therapy progression, stressing resistance mechanisms like MET amplification, value of rebiopsy, individualized use of chemo, TKIs, IO, and trials.
Case 2, presented by Dr. Gainor was a 66-year-old woman with RET fusion lung adenocarcinoma received RT. Panel favored selpercatinib for efficacy, CNS activity, and lower pneumonitis risk.
Dr. Das presented Case 3, a 60-year-old never-smoker with metastatic adenosquamous lung cancer and high PD-L1 responded dramatically to capmatinib after MET14 mutation discovery, highlighting value of targeted therapy.
Case 4, presented by Dr. Bazhenova was of a 26-year-old with HER2 exon 20 lung cancer relapsed after chemo and zangertinib; panel debated next steps including T-DXd and emerging therapies.
Dr. Sanborn presented Case 5, a 67-year-old with BRAF V600E metastatic lung cancer had durable control on BRAF/MEK therapy. With slow progression, panel debated continuing targeted therapy versus switching.
Dr. Alder presented Case 6, a 56-year-old with NTRK fusion lung cancer was treated with larotrectinib. Panel stressed RNA testing to avoid missed fusions and guide targeted therapy.
The wrap up panel discussion reviewed post-targeted therapy progression, stressing resistance mechanisms like MET amplification, value of rebiopsy, individualized use of chemo, TKIs, IO, and trials.
Target Audience
Physicians
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Moderator: Edgardo Santos, MD
Speakers and Panelists:
Nagla Abdel Karim, MD, PhD
Justin F. Gainor, MD
Millie Das, MD
Lyudmila Bazhenova, MD
Rachel E. Sanborn, MD
Laura Alder, MD
Panelists:
Puneeth Iyengar, MD, PhD
David R. Gandara, MD
Date of Release
January 9th, 2026
-1769196766441.webp&w=3840&q=75)
-1769196674841.webp&w=3840&q=75)